AKCA stock forecast
Our latest prediction for Akcea Therapeutics, Inc.'s stock price was made on the April 17, 2018 when the stock price was at 23.93$.
In the short term (2weeks), AKCA's stock price should outperform the market by 3.58%. During that period the price should oscillate between -10.02% and +13.67%.
In the medium term (3months), AKCA's stock price should outperform the market by 0.25%. During that period the price should oscillate between -22.04% and +31.83%.Get email alerts
About Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
At the moment the company generates 212M USD in revenues.
On its last earning announcement, the company reported a loss of -2.00$ per share.
The book value per share is 3.39$
Three months stock forecastApril 17, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|